CAS 956014-19-0

Thiourea, N'-[3,5-bis(trifluoromethyl)phenyl]-N-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]-

CAS : 956014-19-0

Formule : C₁₆H₉BrF₆N₆S

Degré de pureté : 95%

Couleur et forme : Solid

Masse moléculaire : 511.2423

Ref: IN-DA003621

1-(3,5-Bis(Trifluoromethyl)Phenyl)-3-(4-Bromo-2-(2H-Tetrazol-5-Yl)Phenyl)Thiourea

CAS : 956014-19-0

1-(3,5-Bis(Trifluoromethyl)Phenyl)-3-(4-Bromo-2-(2H-Tetrazol-5-Yl)Phenyl)Thiourea

Degré de pureté : 95%

Masse moléculaire : 511.24g/mol

Ref: 54-PC108593

NS 11021

CAS : 956014-19-0

NS 11021

Degré de pureté : ≥95%

Masse moléculaire : 511.24g/mol

Ref: 54-BUP05521

NS 11021

CAS : 956014-19-0

NS 11021 (NS11021) , a novel opener of large-conductance Ca(2+)-activated K(+) channels

Formule : C₁₆H₉BrF₆N₆S

Degré de pureté : 97.26%

Couleur et forme : Solid

Masse moléculaire : 511.24

Ref: TM-T4294

1-[3,5-bis(trifluoromethyl)phenyl]-3-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]thiourea

CAS : 956014-19-0

Degré de pureté : 95%

Masse moléculaire : 511.2399902

Ref: 10-F812004

NS 11021

Produit contrôlé

CAS : 956014-19-0

Formule : C₁₆H₉BrF₆N₆S

Couleur et forme : Neat

Masse moléculaire : 511.242

Ref: TR-N926033

NS 11021

CAS : 956014-19-0

NS 11021 is a drug that inhibits the mitochondrial membrane potential, which is the driving force for ATP synthesis. It can be used to treat bowel disease and cardiac diseases such as hypertrophic cardiomyopathy. NS 11021 also has a pharmacological effect on channels that open in response to an increase in cytosolic calcium levels. This includes atrial and activated potassium channels, which are important for the propagation of action potentials in the heart. NS 11021 can also be used to treat experimental models of ischemia–reperfusion injury due to its ability to inhibit energy metabolism.

Formule : C₁₆H₉BrF₆N₆S

Degré de pureté : Min. 95%

Masse moléculaire : 511.24 g/mol

Ref: 3D-GNB01419